La cadena de opciones muestra datos clave de las opciones de acciones de Rocket Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Rocket Pharmaceuticals..

Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa, Cadena de Opciones

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

Earnings

Earnings Beats

GLOBALFOUNDRIES Q4 2024 Adj. EPS $0.46 Beats $0.44 Estimate, Sales $1.830B Beat $1.829B Estimate

Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) reported quarterly earnings of $2.45 per share which beat the analyst consensus estimate of $2.38 by 2.94 percent. This is a 31.37 percent decrease over earnings of $3.57 per share from the same period last year. The company reported quarterly sales of $6.429 billion which beat the analyst consensus estimate of $6.379 billion by 0.79 percent. This is a 5.48 percent increase over sales of $6.095 billion the same period last year.

Marriott Intl Q4 2024 Adj. EPS $2.45 Beats $2.38 Estimate, Sales $6.429B Beat $6.379B Estimate

Berkshire Hathaway Chairman Warren Buffett has been a legendary figure in investment circles for over half a century, and his stock picks are keenly watched by both experienced and rookie players.
However, the &#8220;Oracle of Omaha&#8221; has remained steadfast in his opposition to cryptocurrencies and related investments, even though some of them may have outperformed the hottest equities in his portfolio.
What happened: In terms of market value, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was Berkshire Hathaway's biggest holding, with a stake worth nearly $70 billion at the end of September, according to an SEC filing.
The Apple position accounted for 26.24% of Berkshire Hathaway's portfolio. Over the last year, the stock has gained 21.64%.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/02/43584910/man-who-accidentally-lost-his-775-million-bitcoin-stash-expresses-desire-to-buy-the-landfill-site">Man Whose $775 Million Bitcoin Fortune Lies Buried In A Landfill Now Wants To Buy The Trash Heap</a>
However, the gains paled in comparison to the returns offered by the iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), the largest Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investment vehicle, launched only a year ago.
Shares of IBIT surged 93.23% in the last year and 64.63% over the last six months.&nbsp;
But despite the impressive returns, the ETF, or any other cryptocurrency investments, have struggled to come on Buffett&#8217;s radar. If anything, Buffett has severely criticized them.
Why It Matters: Despite the impressive returns, the ETF, or any other cryptocurrency investments, have struggled to come on Buffett&#8217;s radar. If anything, Buffett has severely criticized them.
Back in 2018, Buffett famously predicted a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42184221/warren-buffett-once-predicted-a-bad-ending-for-crypto-since-then-the-sectors-market-cap-has-quadrupled-riding-on-the-bitcoin-dogecoin-waves">"bad ending"</a> for cryptocurrencies. As for Bitcoin, the seasoned investor has used considerably more <a href="https://www.benzinga.com/general/24/03/37513063/warren-buffett-says-he-wouldnt-pay-25-for-all-the-bitcoin-in-the-world-he-considers-crypto-rat-poiso">nasty terms,</a> describing it as "rat poison squared."
Notably, the Berkshire Hathaway chairman has made no mention of the asset class in the last few years, despite the total market valuation topping trillions of dollars.
Price Action: Shares of Apple closed 0.01% higher at $227.64 during Monday&#8217;s regular trading session, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;Year-to-date, the stock was down 9.09%.
IBIT shares closed 1.70% higher at $55.40 on Monday and up 4.39% year-to-date.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43581896/analyst-who-nailed-2021-crypto-collapse-now-says-worst-of-bitcoin-could-come-in-next-few-weeks">Analyst Who Nailed 2021 Crypto Collapse Now Says Worst Of Bitcoin Could Come In Next Few Weeks</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

$BTC

$DOGE

AAPL

IBIT

Apple Vs IBIT Bitcoin ETF: One Is Warren Buffett's Berkshire Hathaway's Biggest Holding, The Other Gives Exposure To A Crypto He Vehemently Dislikes, Which Has Generated Better Yearly Returns?

5 analysts have shared their evaluations of Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $51.00 and a low estimate of $40.00. This upward trend is evident, with the current average reflecting a 16.56% increase from the previous average price target of $37.75.
<img src="https://www.benzinga.com/files/images/story/2025/1739275240_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Waystar Holding. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waystar Holding. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waystar Holding compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Waystar Holding's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Waystar Holding's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waystar Holding analyst ratings.</a>
<h2>All You Need to Know About Waystar Holding</h2>
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in better transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for our solutions extends throughout the United States and includes Puerto Rico and other US Territories.
<h3>A Deep Dive into Waystar Holding's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Waystar Holding's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 21.72%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Waystar Holding's net margin excels beyond industry benchmarks, reaching 2.25%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Waystar Holding's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.18% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waystar Holding's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.12%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Waystar Holding: Insights From 5 Analyst Reviews

In the latest quarter, 14 analysts provided ratings for Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Monday.Com, revealing an average target of $334.79, a high estimate of $400.00, and a low estimate of $275.00. Witnessing a positive shift, the current average has risen by 1.93% from the previous average price target of $328.46.
<img src="https://www.benzinga.com/files/images/story/2025/1739275233_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Monday.Com. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$385.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$340.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$300.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$292.00</td>
<td>-</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$300.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$298.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$345.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$302.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Monday.Com. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Monday.Com compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Monday.Com's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Monday.Com's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MNDY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Monday.Com analyst ratings.</a>
<h2>All You Need to Know About Monday.Com</h2>
Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.
<h3>A Deep Dive into Monday.Com's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Monday.Com's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 32.67%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Monday.Com's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -4.79%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Monday.Com's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Monday.Com's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.79%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MNDY

Expert Outlook: Monday.Com Through The Eyes Of 14 Analysts

During the last three months, 7 analysts shared their evaluations of Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Brixmor Property Group, revealing an average target of $30.86, a high estimate of $33.00, and a low estimate of $27.00. This upward trend is apparent, with the current average reflecting a 4.36% increase from the previous average price target of $29.57.
<img src="https://www.benzinga.com/files/images/story/2025/1739275225_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Brixmor Property Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samir Khanal</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Dori Kesten</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Samir Khanal</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Juan Sanabria</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Brixmor Property Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Brixmor Property Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Brixmor Property Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Brixmor Property Group's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Brixmor Property Group analyst ratings.</a>
<h2>All You Need to Know About Brixmor Property Group</h2>
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
<h3>Unraveling the Financial Story of Brixmor Property Group</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Brixmor Property Group's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.35%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Brixmor Property Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 30.15%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Brixmor Property Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.37%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.11%, the company showcases effective utilization of assets.
Debt Management: Brixmor Property Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.85.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Brixmor Property Group

AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) reported quarterly earnings of $4.97 per share which beat the analyst consensus estimate of $4.26 by 16.67 percent. This is a 1 percent decrease over earnings of $5.02 per share from the same period last year. The company reported quarterly sales of $7.21 billion which beat the analyst consensus estimate of $6.80 billion by 6.14 percent. This is a 6.59 percent increase over sales of $6.77 billion the same period last year.

AutoNation Q4 2024 Adj EPS $4.97 Beats $4.26 Estimate, Sales $7.21B Beat $6.80B Estimate

In the preceding three months, 7 analysts have released ratings for Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $32.14, along with a high estimate of $52.00 and a low estimate of $14.00. A decline of 16.52% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1739275212_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Regenxbio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Regenxbio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regenxbio compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Regenxbio's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Regenxbio's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGNX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regenxbio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Regenxbio</h2>
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
<h3>Understanding the Numbers: Regenxbio's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Regenxbio's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -16.31% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Regenxbio's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -246.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Regenxbio's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -18.35% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Regenxbio's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -10.95%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Regenxbio's debt-to-equity ratio surpasses industry norms, standing at 0.28. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGNX

A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts

Guidance

USAC

USA Compression Sees FY25 Adjusted EBITDA Of $590M-$610M

Adjusted EBITDA for the full year 2024 is estimated to be $452 million, a decrease of 2%, compared to 2023, or an increase of 2%, when excluding the disposed business. This includes total credit losses of $47 million in 2024, an increase of $26 million compared to 2023. As previously discussed on the Company's earnings calls, Paysafe made significant investments in 2024 totaling approximately $29 million to expand its sales capabilities and optimize the portfolio.
 &nbsp;

PSFE

Paysafe Expects 2024 Revenue To Be $1.70B (Est $1.722B), An Increase Of 6% Compared To 2023, Or 7% When Excluding Disposed Business

WIIM

Coca-Cola shares are trading higher following better-than-expected Q4 financial results.

Coca-Cola Sees FY25 Adj. EPS Growth 2%-3%, Sees FY25 Free Cash Flow (Ex. Fairlife Payment) ~$9.5B

USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.24 by 25 percent. This is a 800 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $245.900 million which beat the analyst consensus estimate of $243.460 million by 1.00 percent. This is a 9.27 percent increase over sales of $225.049 million the same period last year.

Earnings Misses

USA Compression Partners Q4 2024 GAAP EPS $0.18 Misses $0.24 Estimate, Sales $245.900M Beat $243.460M Estimate

Buybacks

Paysafe Board Authorizes Additional $70M To Existing Share Repurchase Program

On Monday, the U.S. District Court for the District of Massachusetts temporarily blocked the National Institutes of Health (NIH) from cutting research funding in 22 states.
What Happened: On Friday, under updated guidelines, NIH said it would now <a target="_blank" href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-25-068.html" rel="noreferrer noopener">apply</a> a standard indirect cost rate of 15% to all new and existing grants, replacing the previous practice of negotiating separate rates for each grant.
Historically, NIH's average indirect cost rate has been around 27%–28%, with some institutions charging over 50% or even 60%.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
In 2023, NIH awarded over $35 billion in research funding across nearly 50,000 grants. Of this, $26 billion went directly to research, while $9 billion covered indirect costs.
By implementing a 15% rate, NIH aligns more closely with private research funders. Many private foundations, including the Bill &amp; Melinda Gates Foundation, cap indirect costs at 10%–15%, while some do not cover indirect costs at all.
Why It Matters: NIH has a $48 billion budget and 27 institutes that fund critical research on diseases like <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42222191/donald-trump-nominates-pandemic-critic-jay-bhattacharya-tapped-to-reshape-national-institutes-of-health-that-oversees-budget-of-48-billion" rel="noreferrer noopener">cancer and diabetes</a>. The funding cuts were to take effect on Monday, 10 February.
In a social media post, NIH <a target="_blank" href="https://x.com/NIH/status/1888004759396958263?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet&amp;mx=2" rel="noreferrer noopener">said</a> the change would save the federal government $4 billion annually. It said three schools that had charged more than 60% in indirect rates—Harvard University, Yale University, and Johns Hopkins University—had multibillion-dollar endowments.
A complaint <a target="_blank" href="https://coag.gov/app/uploads/2025/02/ECF-001-Complaint-Mass.-v.-NIH-1.pdf" rel="noreferrer noopener">filed</a> earlier on Monday argued that "Without relief from NIH's action, these institutions' cutting-edge work to cure and treat human disease will grind to a halt."
The lawsuit also mentioned, "In issuing the Rate Change Notice, the NIH has also acted beyond its statutory authority and has failed to promulgate the change using notice and comment rulemaking."
The lawsuit adds, "The Rate Change Notice is arbitrary and capricious in, among other ways, its failure to articulate the bases for the categorical rate cap of 15%, its failure to consider the grant recipients' reliance on their negotiated rates, and its disregard for the factual findings that formed the bases for the currently operative negotiated indirect cost rates."
The NIH action will "devastate critical public health research at universities and research institutions," the lawsuit claims.
The complaint alleges that the agency's action will result in layoffs, suspension of clinical trials, disruption of ongoing research programs, and laboratory closures.
Judge Angel Kelley of the U.S. District Court for the District of Massachusetts <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/gdpzkzwrwvw/02102025nih_order.pdf" rel="noreferrer noopener">issued</a> a temporary restraining order asking the 22 states to file a status report in 24 hours and again every two weeks to confirm the regular disbursement of the funds. The judge set a hearing for 21 February.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43608591/taiwan-semiconductors-trillion-dollar-valuation-the-chipmaker-enabling-ai-boom" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor's Trillion-Dollar Valuation: The Chipmaker Enabling AI Boom</a></li>
</ul>
Image via Shutterstock

Biotech

Government

Health Care

General

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

PowerShares Dynamic Healthcare Sector Portfolio

US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget

The transaction includes reseller and merchant contracts, as well as dedicated technology and employees related to the business. The consideration for this transaction largely consists of annual earnout payments over the next five years. The transaction is expected to close in 30 days subject to finalizing certain transition services-related items.
 &nbsp;

Asset Sales

Paysafe Inks Definitive Deal To Sell Its Direct Marketing Payment Processing Business Line; No Terms Disclosed

Coca-Cola Q4 2024 Adj. EPS $0.55 Beats $0.52 Estimate, Sales $11.5B Beat $10.677B Estimate

THRD

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is trading 3.8% lower in pre-market on Tuesday ahead of its second-quarter earnings call scheduled today after the market close.
What Happened: The company&#8217;s management is likely to provide updates on the delayed filing of its annual report for the fiscal year ending June 30, 2024, during the earnings call today. The shares of SMCI surged 17.5% on Monday, a day before its earnings release.
The Nasdaq Exchange has permitted SMCI to submit its 10-K filing until Feb. 25. The San Jose, California-based artificial intelligence company risks delisting if it misses the deadline.
In July, Ernst &amp; Young (EY), then serving as Super Micro&#8217;s auditor, expressed concerns about the company&#8217;s governance and internal controls over financial reporting, prompting the board to establish a special committee. In December, Super Micro issued a statement regarding the special committee being unable to discover material facts backing EY&#8217;s statements, adding that there were no significant concerns regarding the integrity of Super Micro&#8217;s management. Previously, SMCI CEO Charles Liang expressed confidence that the technology company&#8217;s stock will not be delisted from the Nasdaq.
SEE ALSO: <a href="https://www.benzinga.com/news/earnings/25/02/43600652/super-micro-computer-q2-earnings-preview-accounting-updates-nasdaq-deadline-on-watch">Super Micro Computer Q2 Earnings Preview: Accounting Updates, Nasdaq Deadline On Watch</a>
Why It Matters: <a href="https://www.benzinga.com/news/earnings/25/02/43600652/super-micro-computer-q2-earnings-preview-accounting-updates-nasdaq-deadline-on-watch">Wall Street is keenly observing</a> SMCI&#8217;s ongoing accounting issues. Investors are also eager for communication from the company regarding improvements to its financial controls and transparency. This is crucial to reassure shareholders about its governance practices, especially in light of the potential delisting risk.
In a note, Wedbush analyst, Matt Bryson, stated that they believe Supermicro may successfully restate its financials or could also seek a 180-day extension. However, they expressed uncertainty about Super Micro Computer&#8217;s near-term performance, pointing out that competitors such as HP Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) have secured contracts in the artificial intelligence server market.
Bryson has expressed reservations about the company&#8217;s current stock price, citing &#8220;substantial unknowns&#8221; that could negatively impact the share price in the future.
However, Loop Capital Markets analyst&nbsp;Ananda Baruah&nbsp;is upbeat on SMCI and considers it an "important company in an important space" poised to benefit from growth factors like overcoming SEC filing delays and maintaining strong fundamentals.
SMCI stock has plunged more than 44% over the past year.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43591520/dell-vs-hp-ai-server-jpmorgan-pick">Wall Street&#8217;s AI Server Darling? JPMorgan Says It&#8217;s Still Dell</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

SMCI

SMCI Stock Falls Nearly 4% In Tuesday Pre-Market As Investors Await An Update On Delayed Filing

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Jefferies initiated coverage of Rocket Pharmaceuticals (RCKT) with a Buy rating and $29 price target The company has five potentially best- and fir...

Rocket Pharmaceuticals initiated with a Buy at Jefferies

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) on December 20 and set a price ...

Evercore ISI Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)

Yun Zhong, an analyst from Wedbush, has initiated a new Buy rating on Rocket Pharmaceuticals (RCKT). Yun Zhong has given his Buy rating due to a co...

Promising Pipeline and Strategic Developments Propel Rocket Pharmaceuticals to 'Buy' Rating

Wedbush analyst Yun Zhong initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target Published first on The...

Rocket Pharmaceuticals initiated with an Outperform at Wedbush

Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target The analyst believes 2025 "should be an ...

Wedbush starts Rocket Pharmaceuticals with Outperform into 'inflection year'

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) shares were under pressure...

Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The associated price target remai...

Buy Recommendation for Rocket Pharmaceuticals: Promising Potential of RP-L301 in Severe PKD Cases

JPMorgan analyst Eric Joseph lowered the firm's price target on Rocket Pharmaceuticals (RCKT) to $48 from $49 and keeps an Overweight rating on the...

Rocket Pharmaceuticals price target lowered to $48 from $49 at JPMorgan

AMTM

ARQT

ARTV

AXSM

CDTX

CTOR

CTXR

EYEN

HSAI

KULR

MIST

MRNS

MSTR

NAMS

NUVL

NVDA

PGEN

RHHBY

RHHVF

SEAT

SGMO

TLRY

TTWO

VCSA

VSTM

WKSP

Press Releases

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Comments

Rocket Pharmaceuticals

Rocket Pharmaceuticals (RCKT) Opciones

Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL